Collegium Pharmaceutical
COLL
150 hedge funds and large institutions have $648M invested in Collegium Pharmaceutical in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 26 closing their positions.
338% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $579K
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
7% more capital invested
Capital invested by funds: $603M → $648M (+$45.1M)
0.08% more ownership
Funds ownership: 107.72% → 107.81% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 159 → 150 (-9)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$14M |
| 2 |
PA
Perceptive Advisors
New York
|
+$9.91M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$8.14M |
| 4 |
BlackRock
New York
|
+$6.24M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.16M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$4.4M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$3.67M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.23M |
COLL Hedge Fund Activity: Q2 2020 in Review
150 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2020, worth a combined $648M — up 7.5% from $603M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of COLL and 17 opened new positions — a net loss of 9 holders — while 54 trimmed existing stakes and 61 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $14M. The largest seller was Vivo Capital, exiting entirely with an estimated $7.3M sold.
- 150 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2020, down from 159 in Q1 2020.
- Funds reported $648M of Collegium Pharmaceutical stock for Q2 2020, up 7.5% quarter-over-quarter.
- 17 funds opened new Collegium Pharmaceutical positions in Q2 2020 and 26 closed out, a net change of -9 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2020 was Rubric Capital Management (New York), an estimated $14M added.
- The largest Collegium Pharmaceutical seller in Q2 2020 was Vivo Capital, an estimated $7.3M sold.
Based on aggregated 13F filings for Q2 2020.